NRX Pharmaceuticals, Inc. Common Stock (NRXP) is a publicly traded Healthcare sector company. As of October 30, 2026, NRXP trades at $3.03 with a market cap of $116.47M and a P/E ratio of -2.17. NRXP moved +13.72% today. Year to date, NRXP is +10.37%; over the trailing twelve months it is -12.79%. Its 52-week range spans $1.58 to $5.06. Analyst consensus is strong buy with an average price target of $35.00. Rallies surfaces NRXP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NRx wins FDA approval for preservative-free ketamine; U.S. manufacturing with Nephron: NRx Pharmaceuticals received FDA approval for preservative-free ketamine ahead of the November 10 goal date. The company said it will manufacture sterile injectable drugs in the U.S. with Nephron Pharmaceuticals; commercial supply is on hand for labeling and distribution to U.S. hospitals and clinics.
| Metric | Value |
|---|---|
| Price | $3.03 |
| Market Cap | $116.47M |
| P/E Ratio | -2.17 |
| EPS | $-1.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.06 |
| 52-Week Low | $1.58 |
| Volume | 5.53M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.23M |
| Net Income | $-28.62M |
| Gross Margin | 58.78% |
3 analysts cover NRXP: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.00.